GC
BEAM icon

Guggenheim Capital’s Beam Therapeutics BEAM Stock Holding History

Guggenheim Capital’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$855K Buy
35,884
+6,376
+22% +$177K 0.01% 1039
2025
Q4 		$818K Buy
29,508
+1,032
+4% +$26.3K 0.01% 1041
2025
Q3 		$691K Sell
28,476
-5,255
-16% -$105K 0.01% 1057
2025
Q2 		$574K Sell
33,731
-5,918
-15% -$103K ﹤0.01% 1113
2025
Q1 		$774K Buy
39,649
+3,822
+11% +$100K 0.01% 991
2024
Q4 		$889K Sell
35,827
-6,818
-16% -$174K 0.01% 973
2024
Q3 		$1.04M Sell
42,645
-4,434
-9% -$115K 0.01% 1079
2024
Q2 		$1.1M Sell
47,079
-1,316
-3% -$32.3K 0.01% 1073
2024
Q1 		$1.6M Sell
48,395
-3,208
-6% -$99.9K 0.01% 975
2023
Q4 		$1.4M Sell
51,603
-18,390
-26% -$457K 0.01% 993
2023
Q3 		$1.68M Sell
69,993
-16,349
-19% -$438K 0.01% 873
2023
Q2 		$2.76M Buy
86,342
+5,104
+6% +$166K 0.02% 729
2023
Q1 		$2.49M Sell
81,238
-6,620
-8% -$261K 0.02% 775
2022
Q4 		$3.44M Buy
87,858
+328
+0.4% +$14.7K 0.03% 655
2022
Q3 		$4.17M Sell
87,530
-9,409
-10% -$537K 0.04% 577
2022
Q2 		$3.75M Buy
96,939
+5,603
+6% +$223K 0.03% 663
2022
Q1 		$5.23M Buy
91,336
+2,182
+2% +$143K 0.03% 633
2021
Q4 		$7.1M Buy
89,154
+16,846
+23% +$1.44M 0.04% 544
2021
Q3 		$6.29M Buy
72,308
+47,463
+191% +$4.77M 0.04% 565
2021
Q2 		$3.2M Buy
+24,845
New +$1.98M 0.02% 853

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Guggenheim Capital's BEAM Position: Q1 2026 in Review

Guggenheim Capital increased its Beam Therapeutics (BEAM) stake by 22% in Q1 2026, buying an estimated $177K and bringing the position to 35,884 shares worth $855K. The position accounts for 0.01% of the portfolio, ranked #1039.

Guggenheim Capital first reported a position in BEAM in Q2 2021 and has held it in 20 quarters since. The position peaked at $7.1M in Q4 2021. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • Guggenheim Capital held 35,884 shares of Beam Therapeutics worth $855K as of Q1 2026.
  • Guggenheim Capital bought 6,376 Beam Therapeutics shares in Q1 2026, an estimated $177K.
  • Beam Therapeutics made up 0.01% of Guggenheim Capital's portfolio in Q1 2026, its #1039 holding.
  • Guggenheim Capital first reported a position in Beam Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • Guggenheim Capital's Beam Therapeutics position peaked at $7.1M in Q4 2021.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Guggenheim Capital's 13F filing for Q1 2026, filed 15 May 2026.